Trial Profile
Multicenter, no-profit, open, single sequence cross-over study on effectiveness and safety of anti-rejection therapy based on modified release Tacrolimus(Advagraf)and on patients quality of life and adhesion to therapeutical regimen improvement after switch from conventional BID(Prograf) Tacrolimus immunosuppressive therapy to mono-administration of modified release of Tacrolimus in stable kidney transplant recipient
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Dec 2015
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms AQUARIUS
- 04 May 2012 Actual initiation date (21 Feb 2011) added as reported by European Clinical Trials Database.
- 04 May 2012 Planned end date (21 Oct 2012) added as reported by European Clinical Trials Database.
- 23 Mar 2012 New trial record